DEF: Black Diamond Therapeutics Sets Date for 2025 Annual Stockholders Meeting

Black Diamond Therapeutics will hold its 2025 Annual Meeting of Stockholders online on June 12, 2025, to elect directors and ratify the appointment of its accounting firm.

Summary

• Black Diamond Therapeutics will hold its 2025 Annual Meeting of Stockholders online on June 12, 2025, at 9:00 a.m. Eastern Time.
• The meeting will be a virtual meeting conducted via live webcast at www.virtualshareholdermeeting.com/BDTX2025.
• Stockholders of record as of April 14, 2025, are entitled to vote.
• The agenda includes the election of three Class II directors to serve until the 2028 annual meeting, and the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The board of directors recommends voting FOR the election of the director nominees and FOR the ratification of the accounting firm appointment.
• Proxy materials are available online, and a Notice of Internet Availability was mailed to stockholders on or about April 18, 2025.
• Stockholders can vote online, by telephone, or by mail, with specific deadlines for each method.
• As of April 14, 2025, there were 56,676,716 shares of common stock outstanding, each entitled to one vote.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, indicating a neutral but necessary process for corporate governance. The sentiment is moderately positive as it reflects the company's adherence to regulatory requirements and engagement with its shareholders.

Positives

• The virtual-only meeting format enhances stockholder access and participation.
• The company is taking advantage of SEC rules to distribute proxy materials online, reducing environmental impact and costs.
• The board of directors has determined that all members of the board of directors, except Mark A. Velleca, are independent directors, including for purposes of the rules of Nasdaq and the SEC.
• The company has adopted a written code of business conduct and ethics that applies to its directors, officers and employees.
• The company has adopted a compensation recovery policy that provides that in the event we are required to prepare a restatement of financial statements due to material noncompliance with any financial reporting requirement under securities laws, we will seek to recover any incentive-based compensation that was based upon the attainment of a financial reporting measure and that was received by any current or former executive officer during the three-year period preceding the date that the restatement was required if such compensation exceeds the amount that the executive officers would have received based on the restated financial statements.

Risks

• The company's future success depends on its ability to attract, develop and retain key personnel and maintain its culture.
• The biopharmaceutical industry is highly competitive and recruiting and retaining employees is critical to the continued success of our business.
• The company is subject to numerous environmental, health and safety laws and regulations.

Future Outlook

The company is committed to increasing its transparency and further identifying issues that may have a material effect on corporate strategy, risks, opportunities or performance.

Industry Context

This announcement is a routine part of corporate governance for publicly traded companies, ensuring stockholders have the opportunity to participate in key decisions.

Comparison to Industry Standards

• The director compensation program is intended to provide a total compensation package that enables the company to attract and retain qualified and experienced individuals to serve as directors and to align our directors interests with those of our stockholders.
• The company's executive compensation program is based on a pay for performance philosophy.
• The company targets a general competitive position, based on independent third-party benchmark analytics to inform the mix of compensation of base salary, bonus or long-term incentives.

Related Party Transactions

• The company entered into a consulting agreement with KAPital Consulting, LLC, pursuant to which Dr. Dhingra provides certain consulting, advisory and other mutually agreed upon services to the Company from time to time, not to exceed eight (8) days per year.
• In fiscal years 2023 and 2024, the Company paid $50,000 and $37,500, respectively, to Dr. Dhingra in consideration for the services provided to the Company pursuant to the Consulting Agreement.
• In July 2023, the company entered into an Underwriting Agreement with Piper Sandler & Co., as representative of the several underwriters named in Schedule 1 thereto, pursuant to which the company issued and sold 15,000,000 shares of our common stock at the public offering price of $5.00 per share.
• New Enterprise Associates purchased 1,000,000 shares of common stock in the registered public offering for a total purchase price of $5,000,000.

Stakeholder Impact

• Shareholders have the opportunity to vote on key company matters.
• Employees are affected by executive compensation decisions and benefit plans.
• The company's performance and governance impact investor confidence.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will hold the Annual Meeting on June 12, 2025, and announce the voting results.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Board of Directors, Stockholders, Director Election, PricewaterhouseCoopers, Corporate Governance, Executive Compensation, Black Diamond Therapeutics, Audit Committee